2023-06-01 06:55:49
The US Food and Drug Administration (FDA) approved this Wednesday the use of Pfizer’s vaccine to treat respiratory syncytial virus (RSV) for older adults.
It is the second RSV vaccine the FDA has approved this month. Drugmaker GlaxoSmithKline also got the green light from the regulator to market its own serum to treat the disease in older adultspicks up the medium The Hill.
RSV usually causes mild symptoms in healthy children and adults, but for the elderly it can lead to complications.
Between 60,000 and 160,000 people over the age of 65 are hospitalized each year for the disease in the United States. Between 6,000 and 13,000 end up dying, according to The Hill.
In August, Pfizer announced that its vaccine was 85% effective an hour to prevent severe cases of RSV in older adults.
In addition to the vaccine for the elderly, called Abrysvo, the FDA is also considering approving Pfizer’s serum for pregnant women, which seeks to prevent RSV cases in babies.
#FDA #approves #Pfizers #vaccine #respiratory #syncytial #virus